Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?

Journal of the American College of Cardiology

Volumn 53, Issue 8, 2009, Pages 639-647

  Kazory, Amir ^a   Ross, Edward A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

anemia; erythropoietin; ESAs; heart failure; kidney disease

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; BLOOD VISCOSITY; FERRITIN BLOOD LEVEL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT;

ANEMIA; HEART FAILURE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; SYNDROME;

EID: 60049091975     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.10.046     Document Type: Review

References (69)

1. McClellan W.M., Lagston R.D., and Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 15 (2004) 1912-1919
2. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure. J Am Coll Cardiol 47 (2006) 1987-1996
3. Hillege H.L., Girbes A.R.J., de Kam P.J., et al. Renal function, neurohormonal activation, and survival; in patients with chronic heart failure. Circulation 102 (2000) 203-210
4. Collins A.J., Foley R., Herzog C., et al. Excerpts from the United States Renal Data 2007 annual data report. Am J Kidney Dis 51 Suppl 1 (2008) S1-S320
5. Foley R.N., Murray A.M., Li S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 (2005) 489-495
6. Horwich T.B., Fonarow G.C., Hamilton M.A., et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786
7. Sarnak M.J., Tighiouart H., Manjunath G., et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk In Communities (ARIC) study. J Am Coll Cardiol 40 (2002) 27-33
8. Szachniewicz J., Petruk-Kowalczyk J., Majda J., et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 90 (2003) 303-308
9. Arant C.B., Wessel T.R., Olson M.B., et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. J Am Coll Cardiol 43 (2004) 2009-2014
10. Tang Y.D., and Katz S.D. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev 13 (2008) 387-392
11. Young J.B., Abraham W.T., Albert N.M., et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 101 (2008) 223-230
12. Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 51 (2008) 569-576
13. Mitchell J. Emerging role of anemia in heart failure. Am J Cardiol 99 Suppl (2007) 15D-20D
14. Anand I.S. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev 13 (2008) 379-386
15. Palazzuoli A., Gallotta M., Iovine F., et al. Anaemia in heart failure: a common interaction with renal insufficiency called the cardiorenal-anaemia syndrome. Int J Clin Pract 62 (2008) 281-286
16. George J., Patal S., Wexler D., et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Int Med 165 (2005) 1304-1309
17. van der Meer P., Voors A.A., Lipsic E., et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44 (2004) 63-67
18. Kourea K., Parissis J.T., Farmakis D., et al. Effects of darbopoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand systemin anemic patients with chronic heart failure. Atherosclerosis 199 (2008) 215-221
19. Jie K.E., Verhaar M.C., Cramer M.J.M., et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291 (2006) F932-F944
20. Toblli J.E., Lombrana A., Duarte P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007) 1657-1665
21. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol 51 (2008) 103-112
22. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48 (2006) 1225-1227
23. Usmanov R.I., Zueva E.B., Silverberg D.S., and Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe heart failure and chronic kidney insufficiency. J Nephrol 21 (2008) 236-242
24. McClellan W., Aronoff S.L., Bolton W.K., et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20 (2004) 1501-1510
25. Basile J.N. Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease. South Med J 100 (2007) 1200-1207
26. Bahlmann K.H., Kielstein J.T., Haller H., and Fliser D. Erythropoietin and progression of CKD. Kidney Int Suppl 107 (2007) S21-S25
27. Johnson E.S., Thorp M.L., Yang X., et al. Predicting renal replacement therapy and mortality in CKD. Am J Kidney Dis 50 (2007) 559-565
28. Walker A.M., Schneider G., Yeaw J., et al. Anemia as predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 17 (2006) 2293-2298
29. NHLBI Working Group. Cardio-Renal Connections in Heart Failure and Cardiovascular Disease. August 20, 2004. http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm Accessed March 10, 2008
30. Ronco C., House A.A., and Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 34 (2008) 957-962
31. Bongartz L.G., Cramer M.J., Doevendans P.A., et al. The severe cardiorenal syndrome: "Guyton revisited.". Eur Heart J 26 (2005) 11-17
32. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
33. Herzog C.A., Muster H.A., Li S., and Collins A.J. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 10 (2004) 467-472
34. Silverberg D.S., Wexler D., Blum M., et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows down the progression of both diseases. Perit Dial Int 21 Suppl 3 (2001) S236-S240
35. Silverberg D.S., Wexler D., Blum M., et al. The effect of correction of anemia in diabetic and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
36. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
37. Comin-Colet J, Bruguera J, Garcia C, et al. Effect on hospitalization and functional status of correction of mild anemia with subcutaneous erythropoietin and intravenous iron in patients with severe advanced chronic heart failure and mild renal dysfunction. Heart Failure Meeting of the European Society of Cardiology; June 11-16, 2005; Lisbon, Portugal.
38. Delgado R.M., Radovancevic R., van Rossem C.C., Bracey A., and Radovancevic R. Effect of administration of recombinant human erythropoietin in heart failure patients. (abstr). Eur Heart J 25 Suppl 1 (2004) 386A
39. Caro J., Brown S., Miller O., et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93 (1979) 449-458
40. Fehr T., Ammann P., Garzoni D., et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66 (2004) 1206-1211
41. Mason-Garcia M., Beckman B.S., Brookins J.W., et al. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 38 (1990) 969-975
42. van der Putten K., Braam B., Jie K.E., and Gaillard C.A. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 4 (2008) 47-57
43. Levy W.C. Anemia in heart failure. J Am Coll Cardiol 51 (2008) 577-578
44. Pappas K.D., Gouva C.D., Katopodis K.P., et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 and 4): effects on cardiac performance. Cardiovasc Drug Ther 22 (2008) 37-44
45. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
46. Drüeke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
47. Besarab A., Bolton K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
48. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 Suppl 3 (2006) S11-S145
49. Mix T.C., Brenner R.M., Cooper M.E., et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149 (2005) 408-413
50. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
51. Palazzuoli A., Silverberg D., Iovine F., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 (2006) 1096.e9-1096.e15
52. Murphy N.F., and McDonald K. Treatment of anaemia in chronic heart failure-optimal approach still unclear. Eur Heart J 28 (2007) 2185-2187
53. Ponikowski P., Anker S.D., Szachniewicz J., et al. Effect of darbopoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol 49 (2007) 753-762
54. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbopoetin alfa in patients with heart failure and anaemia. Eur Heart J 28 (2007) 2208-2216
55. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbopoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117 (2008) 526-535
56. Brimble K.S., McFarlane A., Winegard N., et al. Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc 34 (2006) 411-420
57. Remuzzi G., and Ingelfinger J.R. Correction of anemia-payoffs and problems. N Engl J Med 355 (2006) 2144-2146
58. Belonje A.M.S., de Boor R.A., and Voors A.A. Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both?. Cardiovasc Drugs Ther 22 (2008) 1-2
59. Locatelli F., and Reigner B.C.E.R.A. : pharmacodynamics, pharmacokinetics, and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 16 (2007) 1649-1661
60. Provenzano R., Besarab A., Macdougall I.C., et al. The continuous erythropoietin activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 67 (2007) 306-317
61. Macdougall I.C., Walker R., Provenzano R., et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results from a randomized clinical trial. Clin J Am Soc Nephrol 3 (2008) 337-347
62. Guglin M.E., and Koul D. Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev 14 (2006) 200-204
63. van Veldhuisen D.J., and McMurray J.J.V. Are erythropoietin stimulating proteins safe and efficacious in heart failure?. Why we need an adequately powered randomized outcome trial. Eur J Heart Fail 9 (2007) 110-112
64. Kazory A., and Ross E.A. Contemporary trends in the pharmacologic and extracorporeal management of heart failure: a nephrologic perspective. Circulation 117 (2008) 975-983
65. Mancini D.M., Katz S.D., Lang C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
66. Felker G.M., Gattis W.A., Leimberger J.D., et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92 (2003) 625-628
67. Golden J.S., Fallick C.C., Josephson S.R., et al. Baseline hematocrit predicts clinical outcomes in heart failure. Circulation 106 Suppl 2 (2002) 3358A
68. Reinecke H., Trey T., Wellmann J., et al. Hemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 24 (2003) 2142-2150
69. Sharma R., Francis D.P., Pitt B., et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25 (2004) 1021-1028